148 related articles for article (PubMed ID: 21658657)
21. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Robak T; Lech-Maranda E; Robak P
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
[TBL] [Abstract][Full Text] [Related]
22. T-cell lymphoid aggregates in bone marrow after rituximab therapy for B-cell follicular lymphoma: a marker of therapeutic efficacy?
Raynaud P; Caulet-Maugendre S; Foussard C; Salles G; Moreau A; Rossi JF; Patey M; Rousselet MC; Bene MC; Damotte D; Cornillet Lefebvre P; Martin A; Costes V;
Hum Pathol; 2008 Feb; 39(2):194-200. PubMed ID: 17949786
[TBL] [Abstract][Full Text] [Related]
23. Cutaneus pseudolymphoma: a case report.
Dragonetti E; Cianchini G; Mastrangelo L; Mellone P; Baldi A
In Vivo; 2004; 18(5):549-51. PubMed ID: 15523891
[TBL] [Abstract][Full Text] [Related]
24. Follow-up data of 10 patients with B-cell non-Hodgkin lymphoma with a CD20-negative phenotypic change after rituximab-containing therapy.
Maeshima AM; Taniguchi H; Fukuhara S; Morikawa N; Munakata W; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Tsuda H
Am J Surg Pathol; 2013 Apr; 37(4):563-70. PubMed ID: 23426122
[TBL] [Abstract][Full Text] [Related]
25. Fatal interstitial lung disease induced by rituximab-containing chemotherapy, treatment with TNF-α antagonist and cytokine profiling: a case-report and review of the literature.
Wu Y; Jia Y; Xu J; Shuai X; Wu Y
J Clin Pharm Ther; 2013 Jun; 38(3):249-53. PubMed ID: 23506410
[TBL] [Abstract][Full Text] [Related]
26. B-cell cutaneous lymphoid hyperplasia representing progressive transformation of germinal center: a report of 2 cases.
Kojima M; Sakurai S; Shimizu K; Itoh H
Int J Surg Pathol; 2010 Oct; 18(5):429-32. PubMed ID: 18815203
[TBL] [Abstract][Full Text] [Related]
27. IgG4-related disease with cutaneous manifestations treated with rituximab: case report and literature review.
Jalilian C; Prince HM; McCormack C; Lade S; Cheah CY
Australas J Dermatol; 2014 May; 55(2):132-6. PubMed ID: 24032760
[TBL] [Abstract][Full Text] [Related]
28. Cutaneous B-cell pseudolymphoma at the site of vaccination.
Cerroni L; Borroni RG; Massone C; Chott A; Kerl H
Am J Dermatopathol; 2007 Dec; 29(6):538-42. PubMed ID: 18032948
[TBL] [Abstract][Full Text] [Related]
29. [Cutaneous B-cell lymphoma treatment with rituximab: two cases].
Viguier M; Bachelez H; Brice P; Rivet J; Dubertret L
Ann Dermatol Venereol; 2002 Oct; 129(10 Pt 1):1152-5. PubMed ID: 12442128
[TBL] [Abstract][Full Text] [Related]
30. Predictive significance of the cut-off value of CD20 expression in patients with B-cell lymphoma.
Horvat M; Kloboves Prevodnik V; Lavrencak J; Jezersek Novakovic B
Oncol Rep; 2010 Oct; 24(4):1101-7. PubMed ID: 20811695
[TBL] [Abstract][Full Text] [Related]
31. Cutaneous lymphoid hyperplasia and other lymphoid infiltrates of the breast nipple: a retrospective clinicopathologic study of fifty-six patients.
Boudova L; Kazakov DV; Sima R; Vanecek T; Torlakovic E; Lamovec J; Kutzner H; Szepe P; Plank L; Bouda J; Hes O; Mukensnabl P; Michal M
Am J Dermatopathol; 2005 Oct; 27(5):375-86. PubMed ID: 16148405
[TBL] [Abstract][Full Text] [Related]
32. Long-term outcome of intravenous therapy with rituximab in patients with primary cutaneous B-cell lymphomas.
Brandenburg A; Humme D; Terhorst D; Gellrich S; Sterry W; Beyer M
Br J Dermatol; 2013 Nov; 169(5):1126-32. PubMed ID: 23796422
[TBL] [Abstract][Full Text] [Related]
33. Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases.
Miserocchi E; Pontikaki I; Modorati G; Gattinara M; Meroni PL; Gerloni V
Autoimmun Rev; 2011 Nov; 11(1):35-9. PubMed ID: 21763790
[TBL] [Abstract][Full Text] [Related]
34. Treatment of primary cutaneous B-cell lymphoma with rituximab.
Fink-Puches R; Wolf IH; Zalaudek I; Kerl H; Cerroni L
J Am Acad Dermatol; 2005 May; 52(5):847-53. PubMed ID: 15858476
[TBL] [Abstract][Full Text] [Related]
35. [Cutaneous follicular center B-cell lymphoma treated with intralesional rituximab].
Gamo R; Calzado L; Pinedo F; López-Estebaranz JL
Actas Dermosifiliogr; 2008 May; 99(4):291-6. PubMed ID: 18394405
[TBL] [Abstract][Full Text] [Related]
36. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma.
Betting DJ; Yamada RE; Kafi K; Said J; van Rooijen N; Timmerman JM
J Immunother; 2009; 32(6):622-31. PubMed ID: 19483647
[TBL] [Abstract][Full Text] [Related]
37. The clinical and biological role of CD20 membrane antigen modulation under immunotherapy with anti-CD20 monoclonal antibody rituximab in lymphoprolipherative neoplastic disorders.
Musto P; D'Auria F
Expert Opin Biol Ther; 2011 May; 11(5):551-7. PubMed ID: 21385115
[TBL] [Abstract][Full Text] [Related]
38. Novel therapeutic option for orbital atypical lymphoid hyperplasia.
Talaulikar D; Tridgell D; Leong D; Dahlstrom JE; Cherian M; Prosser I; Sunderland K
Clin Exp Ophthalmol; 2010 Dec; 38(9):892-4. PubMed ID: 20662847
[TBL] [Abstract][Full Text] [Related]
39. Symmetrical primary cutaneous marginal zone lymphoma associated with rheumatoid arthritis.
Yildirim FE; Karaduman A; Hürmüz P; Ozyar E; Barişta I; Sağlam A
J Cutan Pathol; 2010 May; 37(5):600-4. PubMed ID: 19674036
[TBL] [Abstract][Full Text] [Related]
40. Childhood cutaneous lymphoid hyperplasia following feline scratches.
Madhogaria S; Carr RA; Gach JE
Pediatr Dermatol; 2010; 27(3):294-7. PubMed ID: 20609149
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
